ADAM12 and neoplasm: Accordingly, treatment with anti-AXL activating antibodies59 restored tumor progression in MO5 tumors lacking ADAM12+ cells, and increased the AXL-P+ macrophage level to that in WT mice (Fig. 4k,l), whereas it had no effect on WT tumors.